RESUMEN
INTRODUCCIÓN: En los niños, la bacteriemia debida a Burkholderia cepacia, es considerada una complicación grave y conducente a una elevada mortalidad. Con el objetivo de conocer la mortalidad asociada a esa condición, se realizó una revisión sistemática de la literatura médica. MATERIAL Y MÉTODOS: Se aplicó una estrategia de búsqueda bibliográfica con las palabras claves: "bacteriemia por B. cepacia", "humanos", "niños" y "adolescentes", como únicos filtros. Se informan la mediana y los valores intercuartílicos de la frecuencia de la mortalidad reportada por los estudios incluidos. RESULTADOS: Se identificaron 92 estudios potencialmente útiles. De ellos, se descartaron 81, incluyéndose finalmente, 11 estudios. Se trató de descripciones retrospectivas de casos, salvo uno de ellos, que respondió a un diseño analítico caso-control. La mediana de la mortalidad reportada por esta revisión, fue 0 (Q25 = 0 y Q75 = 28,57%). INTERPRETACIÓN: Si bien la evidencia disponible es escasa y de baja calidad, sugiere que el curso clínico de esta afección no siempre resulta en una elevada mortalidad.
BACKGROUND: Bacteremia due to Burkolderia cepacia in children is considered a severe complication and associated with high mortality incidence. In order to know the level of mortality associated with it, this systematic review of the literature was carried out. METHODS: A search strategy was carried out with the keywords: "bacteremia by B cepacia and human" and "children" and "adolescents" as filters. Global frequency of mortality reported by the included studies was calculated and informed as median (Q2) and its interquartile values (Q1 and Q3). RESULTS: The search identified 92 potentially useful studies. Of these, 81 were discarded, and then remained 11 studies to be included. One out of 11 studies is an analytic case-control design. Rest are retrospective case series. Related mortality median was 0 (Q25 = 0 and Q75 = 28,57%). CONCLUSION: Although the available evidence is scarce and of low quality, it suggests that clinical course of this condition does not always lead to high mortality rates.
Asunto(s)
Humanos , Niño , Bacteriemia/mortalidad , Infecciones por Burkholderia/mortalidad , Burkholderia cepaciaRESUMEN
BACKGROUND: The aim of this study was to assess whether daptomycin is safer and more efficacious than comparators for the treatment of serious infection caused by gram-positive microorganisms. METHODS: Electronic databases (Medline, EMBASE, the Cochrane Central Register of Controlled Trials and clinical registered trials) were searched to identify randomized controlled trials (RCTs) that assessed the efficacy and safety of daptomycin versus therapy with any other antibiotic comparator. Two reviewers independently applied selection criteria, performed a quality assessment and extracted the data. Heterogeneity was assessed, and a random-effects or fixed-effects model, when appropriate, was used for estimates of risk ratio (RR). The primary outcome assessed was the risk of clinical treatment failure among the intention-to-treat population and the presence of any treatment related adverse event (AEs). RESULTS: A total of seven trials fulfilled the inclusion criteria. Daptomycin treatment failure rates were no different to comparator regimens (RR = 0.96; CI 95% 0.86-1.06). No significantly different treatment related AEs were identified when comparing groups (RR = 0.91; CI 95% 0.83-1.01). CONCLUSIONS: No significant differences in treatment failure rates and safety were found using daptomycin or any of the comparators treatment.
RESUMEN
BACKGROUND: Voriconazole is a second-generation triazole. It has excellent bioavailability and broad antifungal spectrum; thus, it is an attractive option for patients at high risk of invasive fungal infections (IFIs). Comparing efficacy and safety of voriconazole with other antifungals in prophylaxis or treatment of IFIs would be useful to draw conclusions regarding prevention and therapeutics of these infections. AIM: To assess efficacy and safety of voriconazole compared with other options as prophylaxis or treatment of IFIs in haematology-oncology patients. MATERIALS AND METHODS: A literature search was performed in MEDLINE database using the search term 'voriconazole' and completed with manual search. STUDY SELECTION: Randomized controlled trials (RCTs) comparing voriconazole with other antifungal agents or placebo. DATA EXTRACTION: Seven studies fulfilled the eligibility criteria. RESULTS: Five studies compared voriconazole to another comparator as prophylaxis of IFIs and two as treatment. Pooled results showed that voriconazole was more effective than the comparator (RR = 1.17; 95%CI = 1.01-1.34), but heterogeneity was significant (Q test 32.7; p = .00001). Sub-analysis according to prophylaxis showed RR = 1.17; 95%CI = 1.00-1.37; while as treatment, RR = 1.23; 95%CI = 0.68-2.22. Risk of adverse events was not different from that observed for the comparator (RR = 1.06, 95%CI = 0.66-1.72) though significant heterogeneity was detected (p < .01). CONCLUSIONS: Voriconazole was as effective and safe as comparators, probably better as prophylaxis than as treatment, but limitations due to variability in the sample size of studies, differences in the age of patients, and heterogeneity between studies' outcome measures indicate the need for further research.
Asunto(s)
Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Huésped Inmunocomprometido/efectos de los fármacos , Voriconazol/administración & dosificación , Voriconazol/efectos adversos , Adolescente , Antifúngicos/uso terapéutico , Niño , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Infecciones Fúngicas Invasoras/prevención & control , Leucemia Mieloide Aguda/complicaciones , Micosis/tratamiento farmacológico , Micosis/prevención & control , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Ensayos Clínicos Controlados Aleatorios como Asunto , Voriconazol/uso terapéutico , Adulto JovenRESUMEN
Las infecciones fúngicas invasivas son una importante causa de morbimortalidad en pediatría. La caspofungina es una equinocandina utilizada como alternativa en la prevención y/o tratamiento de ciertas infecciones fúngicas invasivas en niños, aunque con poca evidencia sobre su eficacia y seguridad en comparación con el tratamiento habitual. Objetivos. Evaluar la eficacia y seguridad de la caspofungina comparada con otros antifúngicos en la prevención y/o tratamiento de infecciones fúngicas invasivas en pediatría. Material y métodos. La estrategia de búsqueda inicial tuvo como objetivo identificar estudios controlados aleatorizados de aceptable calidad metodológica (escala de Jadad > 3) mediante la palabra clave "caspofungin" realizados en pacientes de entre los 0 y los 18 años. Resultados. Solo 3 publicaciones cumplieron los criterios de inclusión. De ellas, 2 fueron en población pediátrica y una en neonatal. No se documentó una mayor incidencia de efectos adversos para la caspofungina y su eficacia no se diferenció de otros antifúngicos (RR típico 1,47; IC 95%: 0,78-2,79). Conclusiones. Esta revisión sistemática sugiere que la caspofungina podría considerarse como una alternativa para su indicación en pediatría en la prevención y tratamiento de las infecciones fúngicas invasivas. Sin embargo, dado el pequeño número de publicaciones existentes, se requieren más estudios para alcanzar conclusiones definitivas.
Invasive fungal infections are a significant cause of morbidity and mortality in children. Caspofungin is an echinocandin used as an alternative treatment in the prevention and/or treatment of certain invasive fungal infections in children, although compared to the standard treatment there is little evidence on its efficacy and safety. Objectives. To evaluate the efficacy and safety of caspofungin compared with other antifungal drugs for the prevention and/or treatment of invasive fungal infections in children. Material and methods. The objective of the initial search strategy was to identify randomized controlled studies of acceptable methodological quality (Jadad scale >3), through the key word "caspofungin", conducted in patients with an age range from 0 to 18 years old. Results. Only 3 publications met the inclusion criteria. Two of them were studies conducted in children and one in newborn infants. A higher incidence of adverse events was not documented for caspofungin and its efficacy was not different from that of other antifungal drugs (typical RR 1.47; CI 95%: 0.78-2.79). Conclusions. This systematic review suggests that caspofungin could be considered as an alternative drug in children for the prevention and treatment of invasive fungal infections. However, given the small number of existing publications, more studies are required to reach definite conclusions.
Asunto(s)
Humanos , Niño , Equinocandinas/uso terapéutico , Lipopéptidos/uso terapéutico , Micosis/tratamiento farmacológico , Antifúngicos/uso terapéutico , Resultado del TratamientoRESUMEN
INTRODUCTION: Invasive fungal infections are a significant cause of morbidity and mortality in children. Caspofungin is an echinocandin used as an alternative treatment in the prevention and/or treatment of certain invasive fungal infections in children, although compared to the standard treatment there is little evidence on its efficacy and safety. OBJECTIVE: To evaluate the efficacy and safety of caspofungin compared with other antifungal drugs for the prevention and/or treatment of invasive fungal infections in children. MATERIALS AND METHODS: The objective of the initial search strategy was to identify randomized controlled studies of acceptable methodological quality (Jadad scale >3), through the key word "caspofungin", conducted in patients with an age range from 0 to 18 years old. RESULTS: The objective of the initial search strategy was to identify randomized controlled studies of acceptable methodological quality (Jadad scale >3), through the key word "caspofungin", conducted in patients with an age range from 0 to 18 years old. CONCLUSIONS: This systematic review suggests that caspofungin could be considered as an alternative drug in children for the prevention and treatment of invasive fungal infections. However, given the small number of existing publications, more studies are required to reach definite conclusions.
INTRODUCCIÓN: Las infecciones fúngicas invasivas son una importante causa de morbimortalidad en pediatría. La caspofungina es una equinocandina utilizada como alternativa en la prevención y/o tratamiento de ciertas infecciones fúngicas invasivas en niños, aunque con poca evidencia sobre su eficacia y seguridad en comparación con el tratamiento habitual. OBJETIVO: Evaluar la eficacia y seguridad de la caspofungina comparada con otros antifúngicos en la prevención y/o tratamiento de infecciones fúngicas invasivas en pediatría. MATERIAL Y MÉTODOS: La estrategia de búsqueda inicial tuvo como objetivo identificar estudios controlados aleatorizados de aceptable calidad metodológica (escala de Jadad ã 3) mediante la palabra clave "caspofungin" realizados en pacientes de entre los 0 y los 18 años. RESULTADOS: Solo 3 publicaciones cumplieron los criterios de inclusión. De ellas, 2 fueron en población pediátrica y una en neonatal. No se documentó una mayor incidencia de efectos adversos para la caspofungina y su eficacia no se diferenció de otros antifúngicos (RR típico 1,47; IC 95%: 0,78-2,79). CONCLUSIONES: Esta revisión sistemática sugiere que la caspofungina podría considerarse como una alternativa para su indicación en pediatría en la prevención y tratamiento de las infecciones fúngicas invasivas. Sin embargo, dado el pequeño número de publicaciones existentes, se requieren más estudios para alcanzar conclusiones definitivas.
Asunto(s)
Antifúngicos/uso terapéutico , Equinocandinas/uso terapéutico , Lipopéptidos/uso terapéutico , Micosis/tratamiento farmacológico , Caspofungina , Niño , Humanos , Resultado del TratamientoRESUMEN
Objective. To evaluate the use of TMP-SMX compared with other options available for the treatment of children with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections. Data Sources. The following databases were searched: Medline and PreMedline (OivdSP interface); Excerpta Medica Database (EMBASE; Elsevier interface); Cumulative Index to the Nursing and Allied Health Literature (CINAHL; EbscoHost interface); Sciences Citation Index Expanded (SCI-EXPANDED; Web of Science interface); Cochrane Library (Wiley interface); Scopus (Elsevier interface), and DARE, HTA (CRD interface). The search strategy was the one developed by SIGN to identify randomized clinical trials and systematic reviews. Also, we conducted a hand review of all reference lists of included studies. No language or data limits were added. The last search was done on October 1, 2015. Main key words were trimethoprim or trimethoprim-sulfamethoxazole combination and Staphylococcus aureus. Study Selection. Only randomized controlled trials comparing TMP-SMX versus any other antibiotic as the first-line treatment in CA-MRSA infections in children were included. Articles were reviewed by 2 reviewers, and in case of discrepancy, the final decision was made by the study coordinator. Data Extraction. Only 27 out of 364 articles identified were randomized controlled trials and only 4 fulfilled the eligibility criteria (Jadad score >3). Data Synthesis. Evidence found only referred to use of TMP-SMX in soft tissue infections. Heterogeneity among studies precluded meta-analysis. Conclusions. Available evidence is not conclusive to promote or refuse TMP-SMX as first-line treatment in CA-MRSA infections in children. Additional well-designed studies are required to fsurther elucidate this issue.